BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xiang S, Song S, Tang H, Smaill JB, Wang A, Xie H, Lu X. TANK-binding kinase 1 (TBK1): An emerging therapeutic target for drug discovery. Drug Discov Today 2021:S1359-6446(21)00248-8. [PMID: 34051368 DOI: 10.1016/j.drudis.2021.05.016] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Chilamakuri R, Rouse DC, Yu Y, Kabir AS, Muth A, Yang J, Lipton JM, Agarwal S. BX-795 inhibits neuroblastoma growth and enhances sensitivity towards chemotherapy. Transl Oncol 2022;15:101272. [PMID: 34823094 DOI: 10.1016/j.tranon.2021.101272] [Reference Citation Analysis]
2 Bailly C. The potential value of amlexanox in the treatment of cancer: Molecular targets and therapeutic perspectives. Biochem Pharmacol 2021;197:114895. [PMID: 34968491 DOI: 10.1016/j.bcp.2021.114895] [Reference Citation Analysis]
3 Shaw LM. TBK1 has a new Akt. J Biol Chem 2021;297:101244. [PMID: 34563542 DOI: 10.1016/j.jbc.2021.101244] [Reference Citation Analysis]